



US0D1068516S

(12)

United States Design Patent

Morelock

(10)

Patent No.:

US D1,068,516 S

(45)

Date of Patent:

** Apr. 1, 2025

(54) WEARABLE SENSOR

FOREIGN PATENT DOCUMENTS

(71) Applicant: Biolinq Incorporated, San Diego, CA (US)

CH 717520 A2 12/2021
EP 3871602 A1 9/2021
(Continued)

(72) Inventor: David Michael Morelock, Escondido, CA (US)

OTHER PUBLICATIONS

(73) Assignee: Biolinq Incorporated, San Diego, CA (US)

Abbot press release (2020). “New late-breaking data show use of Abbott’s Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages.
(Continued)

(**) Term: 15 Years

(21) Appl. No.: 29/885,801

Primary Examiner — Antoine Duval Davis
(74) Attorney, Agent, or Firm — Cooley LLP

(22) Filed: Feb. 28, 2023

(51) LOC (15) Cl. 10-04

(57) CLAIM

(52) U.S. Cl. USPC D10/78; D24/186; D24/216; D10/81

The ornamental design for a wearable sensor, as shown and described.

(58) Field of Classification Search USPC D10/78, 81; D24/108, 134, 186, 187, D24/216

DESCRIPTION

CPC A61M 37/0015; A61M 25/00; A61M 2037/0023; A61M 2037/0046; A61M 2037/0053; A61M 37/00; A61M 2037/0007; A61M 2037/0061; A61M 2205/33; A61M 2205/3303; A61M 2210/04; A61M 2230/20; A61B 5/14503; A61B 5/14514; A61B 5/14532; A61B 5/14546; A61B 5/14865; A61B 5/1495; A61B 5/150022; A61B 5/150282; A61B 5/150427; A61B 5/150969; A61B 5/150984; A61B 5/4839; A61B 5/685;
(Continued)

FIG. 1 is a front perspective view of a wearable sensor showing the new design;
FIG. 2 is a top plan view thereof;
FIG. 3 is a bottom plan view thereof;
FIG. 4 is a left side view thereof;
FIG. 5 is a right side view thereof;
FIG. 6 is a rear view thereof;
FIG. 7 is a front view thereof;
FIG. 8 is a front perspective view of another wearable sensor showing the new design;
FIG. 9 is a top plan view thereof;
FIG. 10 is a bottom plan view thereof;
FIG. 11 is a left side view thereof;
FIG. 12 is a right side view thereof;
FIG. 13 is a rear view thereof; and,
FIG. 14 is a front view thereof.


The broken lines are for the purpose of illustrating portions of the article and form no part of the claimed design.

(56) References Cited

U.S. PATENT DOCUMENTS

4,305,401 A 12/1981 Reissmueller et al.
4,323,996 A 4/1982 Ganter
(Continued)

1 Claim, 14 Drawing Sheets



(58) **Field of Classification Search**

CPC A61B 2562/028; A61B 2562/12; A61B 2562/125; A61B 2560/0242; A61B 2560/0266; A61B 2560/0271; A61B 2560/04; A61B 2560/0406; A61B 2560/0412; A61B 2562/16; A61B 2562/162; A61B 2562/164; A61B 2562/166; A61B 2562/168; A61B 2562/0271; A61B 2562/0272; A61B 5/0008; C12Q 1/006; G01N 27/3271; Y10T 29/49117; A61N 1/0424; A61N 1/044; A61N 1/325; A61N 1/326; A61N 1/327; A61N 1/0476

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,407,295 A 10/1983 Steuer et al.
 5,131,390 A * 7/1992 Sakaguchi A61B 5/4261
 600/573
 5,279,543 A 1/1994 Glikfeld et al.
 5,286,364 A 2/1994 Yacynych et al.
 5,540,828 A 7/1996 Yacynych
 5,730,714 A 3/1998 Guy et al.
 5,766,132 A 6/1998 Yasukawa et al.
 6,036,055 A 3/2000 Mogadam et al.
 6,139,718 A 10/2000 Kurnik et al.
 6,269,053 B1 7/2001 Kawata et al.
 6,284,126 B1 9/2001 Kurnik et al.
 6,413,396 B1 7/2002 Yang et al.
 6,471,903 B2 10/2002 Sherman et al.
 6,603,987 B2 8/2003 Whitson
 6,814,845 B2 11/2004 Wilson et al.
 6,862,466 B2 3/2005 Ackerman
 6,908,453 B2 * 6/2005 Fleming A61B 5/14514
 604/173
 7,097,776 B2 8/2006 Govinda Raju
 7,132,054 B1 11/2006 Kravitz et al.
 7,262,068 B2 8/2007 Roy et al.
 7,343,188 B2 * 3/2008 Sohrab A61B 5/150824
 600/347
 7,344,499 B1 3/2008 Prausnitz et al.
 7,429,333 B2 9/2008 Chiou et al.
 7,456,112 B2 11/2008 Lee
 7,493,232 B1 2/2009 Surina
 8,022,292 B2 9/2011 Arianpour et al.
 8,060,318 B2 11/2011 Vering et al.
 8,088,321 B2 1/2012 Ferguson et al.
 8,094,009 B2 1/2012 Allen et al.
 8,125,331 B2 2/2012 Allen et al.
 8,130,095 B2 3/2012 Allen et al.
 8,280,475 B2 10/2012 Brister et al.
 8,284,046 B2 10/2012 Allen et al.
 8,574,165 B2 11/2013 Marsh
 8,750,955 B2 6/2014 Brister et al.
 8,798,799 B2 8/2014 Deo et al.
 8,909,543 B2 12/2014 Tropper et al.
 D722,697 S 2/2015 Moon et al.
 9,041,730 B2 5/2015 Johnson et al.
 9,055,901 B2 6/2015 Brister et al.
 9,107,623 B2 8/2015 Brauker et al.
 D750,786 S 3/2016 Davies et al.
 D757,000 S 5/2016 Lagomarsino et al.
 9,551,698 B2 1/2017 Huys et al.
 9,717,843 B2 8/2017 Grucela et al.
 9,737,247 B2 8/2017 Wang et al.
 9,743,870 B2 8/2017 Wang et al.
 D810,952 S * 2/2018 Hsu D24/186
 D815,289 S 4/2018 Evers et al.
 D816,229 S 4/2018 Frick et al.
 9,933,387 B1 4/2018 McCanna et al.
 D820,988 S * 6/2018 Pushpala A61N 1/0444
 D24/169
 10,004,435 B2 6/2018 Larvenz et al.

10,029,043 B2 7/2018 Grucela et al.
 10,092,207 B1 10/2018 Windmiller
 D833,023 S * 11/2018 Maletic D24/186
 10,136,846 B2 11/2018 Wang et al.
 D842,996 S 3/2019 Frick et al.
 D845,289 S * 4/2019 Chuang A61B 5/1473
 D14/250
 10,251,565 B2 * 4/2019 Chan A61B 5/14551
 10,321,859 B1 6/2019 Wynbrandt et al.
 10,362,973 B2 7/2019 Hernandez-Rosas et al.
 D867,911 S * 11/2019 Alabdin A61B 5/14551
 D10/104.1
 10,492,708 B1 12/2019 Windmiller
 D875,254 S * 2/2020 Cooke A61B 5/7405
 D24/169
 D882,432 S * 4/2020 Yee A61B 5/7405
 D24/186
 10,765,369 B2 * 9/2020 Antonio A61B 5/1473
 11,039,767 B2 6/2021 Hayter
 11,045,142 B1 6/2021 Windmiller et al.
 D928,150 S * 8/2021 Maruyama D21/333
 11,087,868 B2 8/2021 Budiman
 11,102,306 B2 8/2021 Mensinger et al.
 D929,990 S * 9/2021 Maruyama D24/186
 11,141,116 B2 10/2021 Cabrera, Jr. et al.
 11,150,145 B2 10/2021 Nekoomaram et al.
 11,154,253 B2 10/2021 Cabrera, Jr. et al.
 11,182,332 B2 11/2021 Anderson et al.
 11,197,626 B2 12/2021 Koehler et al.
 11,205,511 B2 12/2021 Hayter et al.
 11,207,025 B1 * 12/2021 Trapero Martin A61B 5/308
 11,272,890 B2 3/2022 McGarraugh
 11,305,906 B2 4/2022 Grucela et al.
 11,357,430 B2 6/2022 Pushpala et al.
 11,373,347 B2 6/2022 Kamath et al.
 D957,438 S 7/2022 Hayter et al.
 D958,817 S 7/2022 Mensinger et al.
 11,389,088 B2 7/2022 Desborough et al.
 D960,895 S 8/2022 Mensinger
 11,406,331 B2 8/2022 Budiman
 11,406,818 B2 8/2022 Windmiller
 11,437,141 B2 9/2022 Mensinger et al.
 11,446,108 B2 9/2022 Larson et al.
 D967,128 S 10/2022 Kumar et al.
 D967,136 S 10/2022 Kumar et al.
 11,464,459 B2 10/2022 Sjolund et al.
 11,475,988 B1 10/2022 Burkart et al.
 11,497,422 B2 11/2022 Koehler et al.
 11,507,530 B2 11/2022 Anderson et al.
 11,517,222 B2 12/2022 Pushpala et al.
 11,534,089 B2 12/2022 Taub et al.
 11,547,799 B2 1/2023 Zhong et al.
 11,576,600 B2 * 2/2023 Lee A61B 5/257
 11,654,270 B2 5/2023 Mansfield, III et al.
 11,660,392 B2 * 5/2023 Kamen A61M 5/14244
 604/151
 D988,160 S 6/2023 Morelock
 11,672,965 B2 6/2023 Mansfield et al.
 D996,999 S * 8/2023 Morelock D24/186
 D1,010,133 S * 1/2024 Yee G16H 40/63
 D24/186
 D1,012,292 S * 1/2024 Armstrong D24/186
 11,857,344 B2 1/2024 Windmiller et al.
 11,872,055 B2 1/2024 Tangney et al.
 D1,013,544 S * 2/2024 Morelock D24/186
 D1,035,004 S * 7/2024 Morelock D24/169
 2003/0225360 A1 * 12/2003 Eppstein A61N 1/044
 604/19
 2006/0015061 A1 1/2006 Kuo et al.
 2007/0170054 A2 7/2007 Wilsey
 2007/0213044 A1 9/2007 Steingart et al.
 2009/0088652 A1 4/2009 Tremblay
 2009/0143761 A1 * 6/2009 Cantor A61N 1/0444
 604/501
 2009/0259118 A1 10/2009 Feldman et al.
 2010/0056873 A1 3/2010 Allen et al.
 2010/0286803 A1 11/2010 Tillotson et al.
 2012/0323097 A9 12/2012 Chowdhury

(56)

References Cited

U.S. PATENT DOCUMENTS

2013/0065257	A1	3/2013	Wang et al.	
2013/0144131	A1	6/2013	Wang et al.	
2014/0259652	A1	9/2014	Pushpala et al.	
2014/0275897	A1 *	9/2014	Pushpala	 A61B 5/150427 600/347
2014/0336487	A1	11/2014	Wang et al.	
2015/0335272	A1	11/2015	Natale et al.	
2017/0003766	A1	1/2017	Budiman	
2017/0055851	A1	3/2017	Al-Ali	
2017/0215774	A1	8/2017	Koehler et al.	
2018/0249937	A1	9/2018	Wiese et al.	
2019/0095602	A1	3/2019	Setlak et al.	
2019/0125223	A1	5/2019	Wang et al.	
2019/0167167	A1	6/2019	Mitchell et al.	
2019/0246914	A1	8/2019	Constantin et al.	
2019/0246973	A1	8/2019	Constantin et al.	
2019/0274603	A1	9/2019	Ringemann	
2019/0307376	A1	10/2019	Hernandez-Rosas et al.	
2019/0309433	A1	10/2019	Sattayasamitsathit et al.	
2020/0085341	A1	3/2020	Windmiller	
2020/0101286	A1	4/2020	Windmiller et al.	
2020/0146598	A1	5/2020	Mayou et al.	
2020/0214566	A1	7/2020	Allen et al.	
2020/0245914	A1	8/2020	Bhavaraju et al.	
2020/0254240	A1	8/2020	Windmiller et al.	
2020/0275870	A1	9/2020	Bhavaraju et al.	
2020/0297997	A1	9/2020	Windmiller et al.	
2020/0337615	A1	10/2020	Larvenz et al.	
2021/0161436	A1	6/2021	Troncelliti et al.	
2021/0169384	A1	6/2021	Taub et al.	
2021/0187286	A1	6/2021	Windmiller et al.	
2021/0196162	A1	7/2021	Halac et al.	
2021/0236057	A1	8/2021	Pushpala et al.	
2021/0282672	A1	9/2021	Kumar et al.	
2021/0321914	A1	10/2021	Brister et al.	
2021/0335499	A1	10/2021	Simpson et al.	
2021/0361199	A1	11/2021	Kumar	
2021/0378601	A1	12/2021	Kumar et al.	
2021/0393201	A1	12/2021	Morelock et al.	
2022/0000399	A1	1/2022	Hayter et al.	
2022/0000432	A1	1/2022	Cabrera, Jr. et al.	
2022/0031209	A1	2/2022	Windmiller et al.	
2022/0031244	A1	2/2022	Windmiller et al.	
2022/0057868	A1	2/2022	Budiman	
2022/0080678	A1	3/2022	Cole et al.	
2022/0087610	A1	3/2022	Pushpala et al.	
2022/0101995	A1	3/2022	Johnson et al.	
2022/0142524	A1	5/2022	Harper et al.	
2022/0142589	A1	5/2022	Lee	
2022/0175278	A1	6/2022	Campbell et al.	
2022/0194644	A1	6/2022	Grucela et al.	
2022/0202319	A1	6/2022	Crawford et al.	
2022/0202320	A1	6/2022	Diener et al.	
2022/0216735	A1	7/2022	Yan et al.	
2022/0265224	A1	8/2022	Hauptman et al.	
2022/0283042	A1	9/2022	Nekoomaram et al.	
2022/0292746	A1	9/2022	Kamath et al.	
2022/0336100	A1	10/2022	Chiu et al.	
2022/0361825	A1	11/2022	Kang	
2022/0370011	A1	11/2022	Windmiller et al.	
2022/0392643	A1	12/2022	Mensinger et al.	
2023/0005588	A1	1/2023	Sokolovskyy et al.	
2023/0074798	A1	3/2023	Tangney et al.	
2023/0094419	A1	3/2023	Mansfield, III et al.	
2023/0099617	A1	3/2023	Mansfield, III et al.	
2023/0137258	A1	5/2023	Windmiller	
2023/0190147	A1	6/2023	Campbell et al.	
2023/0256220	A1	8/2023	Mansfield, III et al.	
2023/0301552	A1	9/2023	Mallires et al.	
2023/0310823	A1	10/2023	Mansfield et al.	
2023/0414102	A1	12/2023	Allen et al.	
2024/0008777	A1	1/2024	Fuchs et al.	

FOREIGN PATENT DOCUMENTS

FR	3042872	B1	12/2020
JP	1721016	S	7/2022
WO	WO-2009034313	A2	3/2009
WO	WO-2009034313	A3	3/2009
WO	WO-2009064164	A2	5/2009
WO	WO-2009064164	A3	5/2009
WO	WO-2010120364	A2	10/2010
WO	WO-2010120364	A3	10/2010
WO	WO-2012020332	A2	2/2012
WO	WO-2012020332	A3	2/2012
WO	WO-2013058879	A2	4/2013
WO	WO-2013058879	A3	4/2013
WO	WO-2020073060	A1	4/2020
WO	WO-2021148596	A1	7/2021
WO	WO-2022044017	A1	3/2022
WO	WO-2022031792	A9	4/2022
WO	WO-2022044018	A3	4/2022
WO	WO-2022266443	A1	12/2022
WO	WO-2023055755	A1	4/2023
WO	WO-2023064877	A1	4/2023
WO	WO-2023133468	A1	7/2023
WO	WO-2023229662	A2	11/2023
WO	WO-2024010827	A1	1/2024

OTHER PUBLICATIONS

Al Hayek et al., "Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study" *Cureus* Oct. 27, 2020; 12(10):e11195. 8 pages. doi: 10.7759/cureus.11195.

Allen et al., "Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial" *Diabetes Res Clin Pract.* Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006.

American Diabetes Association® Press Release (2020). "American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans," 4 pages. Bantle, J.P. et al. (1997). "Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid," *J. Lab. Clin. Med.* 130:436-441.

Barrett et al., "Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 Years—United States, Mar. 1, 2020-Jun. 28, 2021" *MMWR Morb Mortal Wkly Rep.* Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2.

Beckles, G.L. et al. (2016). "Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014," *MMWR* 65:1265-1269.

Biolinq, Inc. (2019). *The Intelligent Continuous Glucose Monitoring System*, 5 total pages.

Cao, J et al. (2017). "Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system," *Pract. Lab. Med.* 9:24-27.

Castle, J.R. et al. (2012). "The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes," *Diabetes Care* 35:706-710.

Centers for Disease Control, "National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States" (2020) 32 pages.

Dexcom (2020). *Analyst Day Presentation*, 19 total pages.

Dexcom (2020). *Analyst Day Presentation*, 27 total pages.

Diabetes Care (2021). "7. Diabetes Technology: Standards of Medical Care in Diabetes—2021," *Diabetes Care* 44(Supplement 1):S85-S99.

Dunkin et al., "Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers" *Plast Reconstr Surg.* May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0.

Ehrhardt et al., "Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring" *Journal of Diabetes Science and Technology* Mar. 2019; 13(2):271-275.

(56)

References Cited

OTHER PUBLICATIONS

Ehrhardt et al., "Continuous Glucose Monitoring As a Behavior Modification Tool" Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037.

Ehrhardt et al., "The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus" Journal of Diabetes Science and Technology May 2011; 5(3):668-675.

Fang, M. et al. (2021). "Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018," N. Engl. Med. 384:2219-2228.

Fonda et al., "The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes" Journal of Diabetes Science and Technology (2016) 10(4):898-904.

French, D.P. et al. (2008). "Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial," Diab. Med. 25:1218-1228.

Grady, M. et al. (2017). "Examining the Impact of a Novel Blood Glucose Monitor with Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level," JMIR Diabetes 2:e24. 11 pages.

Grady, M. et al. (2018). "Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (Accents Study)," J. Diab. Sci. Tech. 12:1211-1219.

Groenendaal, W. et al. (2008). "Modeling Glucose and Water Dynamics in Human Skin," Diab. Tech. Therap. 10:283-293.

Han et al., "The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?" Journal of Diabetes Science and Technology (2020) 14(3):595-600.

Han et al., "The YSI 2300 Analyzer Replacement Meeting Report" Journal of Diabetes Science and Technology (2020) 14(3):679-686.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). "Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes," N. Engl. Med. 359:1464-1476.

Karter, A.J. et al. (2021). "Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes," JAMA 325:2273-2284.

Martens, T. et al. (2021). "Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin A Randomized Clinical Trial," JAMA 325:2262-2272.

McClatchey, P.M. et al. (2019). "Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays," Diabetes 68:1892-1901.

Neerken, S. et al. (2004). "Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography," J. Biomed. Optics 9:274-281.

Non-Final Office Action mailed on Nov. 14, 2019, for U.S. Appl. No. 29/650,794, filed Jun. 8, 2018, 10 pages.

Notice of Allowance mailed on Dec. 18, 2019, for U.S. Appl. No. 29/650,794, filed Jun. 8, 2018, 7 pages.

Notice of Allowance mailed on Sep. 29, 2022, for U.S. Appl. No. 29/774,399, filed Mar. 16, 2021, 7 pages.

Notice of Allowance mailed on Jan. 25, 2023, for U.S. Appl. No. 29/774,399, filed Mar. 16, 2021, 11 pages.

Notice of Allowance mailed on Mar. 1, 2023, for U.S. Appl. No. 29/815,797, filed Nov. 16, 2021, 10 pages.

Notice of Allowance mailed on May 17, 2023, for U.S. Appl. No. 29/836,984, filed Apr. 29, 2022, 7 pages.

Notice of Allowance mailed on May 31, 2023, for U.S. Appl. No. 29/838,870, filed May 16, 2022, 7 pages.

Notice of Allowance mailed on Jun. 14, 2023, for U.S. Appl. No. 29/815,797, filed Nov. 16, 2021, 9 pages.

Polonsky, W.H. et al. (2011). "A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?" Curr. Med. Res. & Opinion 27:31-37.

Rigla, M. et al. (2018). "Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy," Diabetes Technology & Therapeutics 20:296-302.

Sharifi et al., "Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring" Journal of Diabetes Science and Technology (2016) 10(3):669-678.

Sheikh, Z. et al. (2015). "Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials," Materials 8:5671-5701.

Shi, T. et al. (2016). "Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes," J. Diab. Res. vol. 2016, 9 pages.

Turner et al., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" The Lancet Sep. 1998; 352(9131):837-853.

Vigersky et al., "Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes" Diabetes Care Jan. 2012; 35:32-38.

Wolicki et al., "Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration" Centers for Disease Control and Prevention (2021) 17 pages.

World Health Organization, "Diabetes", Sep. 16, 2022, 5 pages.

Young et al., "Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial" JAMA Intern Med. Jul 2017; 177(7):920-929.

Notice of Allowance mailed on Nov. 22, 2023, for U.S. Appl. No. 29/838,870, filed May 16, 2022, 7 pages.

Notice of Allowance mailed on Nov. 29, 2023, for U.S. Appl. No. 29/836,984, filed Apr. 29, 2022, 7 pages.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14